Watchlist

Watchlist
Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (FOLD)
Amicus submits U.S. marketing application for Fabry med migalastat; shares up 2% premarket
Amicus Therapeutics (NASDAQ: FOLD ) is up 2% premarket, albeit on only 200 shares, in response to its announcement that it has filed a New Drug Application (NDA) with the FDA seeking approval for migalastat for the patients at least 16 years old with Fabry disease who have amen…
ROTY Edition 1 Volume 61: ASH Updates And Trades
Welcome to the 61st entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
ROTY Edition 1 Volume 60: Updates And Trades
Welcome to the 60th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
ROTY Edition 1 Volume 59: Updates And Trades
Welcome to the 59th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
Amicus Therapeutics: Upside Via Regulatory Updates And Pompe Program
Shares of Amicus Therapeutics ( FOLD ) have risen by over 150% since I called them " undervalued with catalysts on the way " last December, but have traded flat since my update piece in late July. FOLD data by YCharts In my last article I touched on the original thesis involving the…
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: …
Amicus Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2017 Q3 earnings Read more …
Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2017 Results - Earnings Call Transcript
Amicus Therapeutics, Inc. (FOLD) Q3 2017 Earnings Conference Call November 08, 2017, 08:30 ET Executives Sara Pellegrino - Senior Director, IR John Crowley - Chairman and CEO Bradley Campbell - President and COO William Baird - CFO Analysts Anupam Rama - JPMorgan Chase &…
Amicus Therapeutics misses by $0.10, beats on revenue
Amicus Therapeutics (NASDAQ: FOLD ): Q3 EPS of -$0.41 misses by $0.10 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more …
Notable earnings before Wednesday's open
ALSK , AVDL , BR , BTG , CABO , CARS , CECE , CNDT , ECA , EFOI , EGLT , EGN , EGRX , ENR , FOLD , FTK , GDP , GIB , GLP , GPN , HII , HPT , HRI , HSC , HSNI , HUM , ICL , ITCI , KELYA , LINC , LXRX , MACK , MCRB , MGM , MGP , NHI , OPHT , PCRX , PFGC …
Amicus Therapeutics, Inc. (FOLD)